V Craig Jordan

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. pmc Targeting oestrogen to kill the cancer but not the patient
    J S Lewis
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Olson Pavilion, Room 8258, Chicago, IL 60611, USA
    Br J Cancer 90:944-9. 2004
  2. ncbi request reprint Molecular classification of estrogens
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Cancer Res 61:6619-23. 2001
  3. ncbi request reprint Tamoxifen: a most unlikely pioneering medicine
    V Craig Jordan
    The Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue, Olson Pavilion 8258, Chicago, Illinois 60611, USA
    Nat Rev Drug Discov 2:205-13. 2003
  4. ncbi request reprint Changing role of the oestrogen receptor in the life and death of breast cancer cells
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Breast 12:432-41. 2003
  5. pmc A new day dawns: women without oestrogen or is a balance best?
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Breast Cancer Res 4:218-21. 2002
  6. ncbi request reprint Selective estrogen receptor modulation: concept and consequences in cancer
    V Craig Jordan
    Northwestern University, Chicago, IL, USA
    Cancer Cell 5:207-13. 2004
  7. ncbi request reprint The secrets of selective estrogen receptor modulation: cell-specific coregulation
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Cancer Cell 1:215-7. 2002
  8. ncbi request reprint Tamoxifen: a personal retrospective
    V C Jordan
    Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611 3008, USA
    Lancet Oncol 1:43-9. 2000
  9. pmc Introducing a new section to Breast Cancer Research: endocrinology and hormone therapy
    V Craig Jordan
    Lynn Sage Breast Cancer Research Program, Northwestern University Medical School, Chicago, Illinois, USA
    Breast Cancer Res 5:281-3. 2003
  10. ncbi request reprint The past, present, and future of selective estrogen receptor modulation
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Ann N Y Acad Sci 949:72-9. 2001

Research Grants

  1. EFFECT OF RALOXIFENE ON SALIVARY STEROIDS
    VIRGIL JORDAN; Fiscal Year: 2002
  2. Pharmacogenetics of Sulfate Conjugation
    VIRGIL JORDAN; Fiscal Year: 2006

Collaborators

Detail Information

Publications53

  1. pmc Targeting oestrogen to kill the cancer but not the patient
    J S Lewis
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Olson Pavilion, Room 8258, Chicago, IL 60611, USA
    Br J Cancer 90:944-9. 2004
    ....
  2. ncbi request reprint Molecular classification of estrogens
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Cancer Res 61:6619-23. 2001
    ..Phytoestrogens and environmental xenoestrogens will fall into different classes based on structure and may exhibit selective actions and carcinogenic potential based on different ER conformations...
  3. ncbi request reprint Tamoxifen: a most unlikely pioneering medicine
    V Craig Jordan
    The Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue, Olson Pavilion 8258, Chicago, Illinois 60611, USA
    Nat Rev Drug Discov 2:205-13. 2003
    ..However, 40 years ago, it was hard to imagine that a non-toxic targeted treatment for breast cancer could be developed at all...
  4. ncbi request reprint Changing role of the oestrogen receptor in the life and death of breast cancer cells
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Breast 12:432-41. 2003
    ..These new data build on the idea that breast cancer can be controlled as a chronic disease and will permit patients to live long and productive lives during targeted maintenance treatment...
  5. pmc A new day dawns: women without oestrogen or is a balance best?
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Breast Cancer Res 4:218-21. 2002
    ..It is now clear that strategies utilising aromatase inhibitors and selective oestrogen receptor modulators will provide much needed options for individualised treatments...
  6. ncbi request reprint Selective estrogen receptor modulation: concept and consequences in cancer
    V Craig Jordan
    Northwestern University, Chicago, IL, USA
    Cancer Cell 5:207-13. 2004
    ..The future exploitation of these novel data will allow selective killing of cancer with fewer side effects for patients...
  7. ncbi request reprint The secrets of selective estrogen receptor modulation: cell-specific coregulation
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Cancer Cell 1:215-7. 2002
    ..A specific increase in the level of a single coactivator appears to enhance estrogen action with tamoxifen at some gene targets in uterine cells but not breast cells...
  8. ncbi request reprint Tamoxifen: a personal retrospective
    V C Jordan
    Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611 3008, USA
    Lancet Oncol 1:43-9. 2000
    ..One of these compounds, raloxifene, is used for the prevention of osteoporosis, but is currently being tested as a preventive for breast cancer...
  9. pmc Introducing a new section to Breast Cancer Research: endocrinology and hormone therapy
    V Craig Jordan
    Lynn Sage Breast Cancer Research Program, Northwestern University Medical School, Chicago, Illinois, USA
    Breast Cancer Res 5:281-3. 2003
    ..Breast Cancer Research is launching a new section on endocrinology and hormone therapy in order to invigorate this exchange and challenge our readers with novel concepts that might result in enhanced survival in breast cancer...
  10. ncbi request reprint The past, present, and future of selective estrogen receptor modulation
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Ann N Y Acad Sci 949:72-9. 2001
    ..Future studies of the signal transduction pathways of the ER alpha (alpha)- and beta (beta)-SERM complexes hold the promise of new drug discoveries and a menu of preventive medicine in clinical practice...
  11. ncbi request reprint Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture
    V C Jordan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Ann N Y Acad Sci 952:60-72. 2001
    ..The future development of SERMs holds the promise of preventing osteoporosis and coronary heart disease as well as breast and endometrial cancer...
  12. ncbi request reprint Tamoxifen, raloxifene and the prevention of breast cancer
    D J Bentrem
    Departments of Surgery, Molecular Pharmacology and Biological Chemistry, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School Chicago, USA
    Minerva Endocrinol 27:127-39. 2002
    ..This knowledge can be used to design new SERMs and advance the prospects for multifunctional medicine to prevent breast cancer, osteoporosis and coronary heart disease...
  13. pmc Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells
    Hong Liu
    Robert H Lurie Comprehensive Cancer Center and the Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA
    J Biol Chem 277:9189-98. 2002
    ..Alteration of either the side chain or its relationship with the negative charge at amino acid 351 controls the estrogen-like action at activating function 2b of the selective estrogen receptor modulator ERalpha complex...
  14. ncbi request reprint Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex
    Bin Chen
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Oncol 27:327-35. 2005
    ..We conclude that endogenous ERbeta may not play a dominant role in the modulation of the tamoxifen ERalpha complex, or in the development of tamoxifen-stimulated resistant tumor growth...
  15. ncbi request reprint Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12
    Sandra Timm Pearce
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Biol Chem 278:7630-8. 2003
    ..D538A complex. These data further illustrate the complex role of specific surface amino acids in the modulation of the concentration and the estrogenicity of the 4-OHT.ER complex...
  16. ncbi request reprint Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells
    Debra A Tonetti
    Department of Biopharmaceutical Sciences, College of Pharmacy M C 865, University of Illinois at Chicago, 833 S Wood Street, Chicago, IL 60612, USA
    J Steroid Biochem Mol Biol 87:47-55. 2003
    ..In summary, the availability of both ERalpha and ERbeta stable breast cancer cell lines now allows us to compare and contrast the long-term consequences of individual signal transduction pathways...
  17. ncbi request reprint Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Clodia Osipo
    Department of Pathology, Oncology Institute, Cardinal Bernadin Cancer Center, Loyola University Medical Center, Maywood, IL, USA
    Int J Oncol 30:509-20. 2007
    ....
  18. ncbi request reprint In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer
    Hiroyuki Takei
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, USA
    Breast Cancer 9:39-42. 2002
    ..In this study we investigated the in vitro effects of antiestrogens at different concentrations on vascular endothelial growth factor (VEGF) production in estrogen receptor (ER)-positive breast cancer cells...
  19. ncbi request reprint Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine of Northwestern University, 303 East Chicago Avenue, MS N505, Chicago, Illinois 60611, USA
    J Med Chem 46:1081-111. 2003
  20. ncbi request reprint Models of hormone resistance in vitro and in vivo
    Jennifer MacGregor Schafer
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Methods Mol Med 120:453-64. 2006
    ..However, there is an evolution of drug resistance to anti-hormones. This is evidenced by a change in sensitivity to estrogen. The natural hormone no longer stimulated tumor growth but causes apoptosis and tumor regression...
  21. ncbi request reprint Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
    Robert T Chatterton
    Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Endocrinol 191:599-604. 2006
    ..The results reflect increases in serum oestradiol reported earlier...
  22. ncbi request reprint Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 95:1597-608. 2003
    ..We investigated the molecular mechanism(s) of estradiol-induced tumor regression by using an in vivo model of tamoxifen-stimulated human breast cancer...
  23. ncbi request reprint Trastuzumab therapy for tamoxifen-stimulated endometrial cancer
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Cancer Res 65:8504-13. 2005
    ..However, trastuzumab is a better growth inhibitor of ECC-1TAM tumors where there is diminished IGF-I signaling allowing for complete blockade of the downstream phospho-ERK-1/2 signal...
  24. ncbi request reprint Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice
    Ruth M O'Regan
    Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 94:274-83. 2002
    ..We evaluated the effects on tumor growth of raloxifene, another SERM, after tamoxifen treatment in mouse models of breast and endometrial cancers...
  25. ncbi request reprint Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha
    Sandra Timm Pearce
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Cancer Res 64:2889-97. 2004
    ..This study provides the first evidence for the direct interaction of the ER with MCDF and challenges the view that MCDF is simply an AhR-specific ligand...
  26. ncbi request reprint Role of antiestrogens and aromatase inhibitors in breast cancer treatment
    David J Bentrem
    Department of Surgery, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Curr Opin Obstet Gynecol 14:5-12. 2002
    ..Additionally, two different classes of hormonal agents, the aromatase inhibitors and estrogen receptor down-regulators, which have no estrogen-like properties at any site, appear to be promising new treatments for advanced breast cancer...
  27. ncbi request reprint Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
    Woo Chan Park
    Lynn Sage Breast Cancer Research Program, Robert H Lurie Comprehensive Cancer Center, Olson Pavilion 8258, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Trends Mol Med 8:82-8. 2002
    ..Emerging knowledge about the action of SERMs will provide clues for the design of mechanism-based medicines...
  28. ncbi request reprint The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators
    Ruth M O'Regan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Lancet Oncol 3:207-14. 2002
    ..Furthermore, two different classes of hormonal agents, the aromatase inhibitors and oestrogen-receptor downregulators, which have no oestrogen-like properties at any site, are promising new treatments for breast cancer...
  29. ncbi request reprint Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade
    Csaba Gajdos
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Clin Breast Cancer 2:272-81. 2002
    ....
  30. ncbi request reprint A mechanism of drug resistance to tamoxifen in breast cancer
    Jennifer MacGregor Schafer
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Olson Pavilion 8258, 303 East Chicago Avenue, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 83:75-83. 2002
    ..Three phases of tumor progression are described that involve increases in HER-2/neu expression, de-regulation of estrogen receptor expression and increases in apoptosis which in concert determine the phenotype of drug resistance to Tam...
  31. ncbi request reprint Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo
    Hong Liu
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 95:1586-97. 2003
    ..We developed a raloxifene-resistant MCF-7 cell model (MCF-7/Ral) and investigated the nature of raloxifene-resistant breast cancer and its response to estradiol...
  32. ncbi request reprint Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 93:249-56. 2005
    ..Based on the results, we suggest using an alternating treatment regimen, cycling antiestrogen with estrogen therapy to avoid drug-resistance...
  33. ncbi request reprint Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women
    Robert T Chatterton
    Department of Obstetrics Gynaecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Endocrinol 186:77-84. 2005
    ..In addition, it emphasizes the importance of sampling at multiple time points when examining the relationship between hormones and risk...
  34. ncbi request reprint The evolving role of endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 850, Chicago, IL 60611 2927, USA
    Cancer Chemother Biol Response Modif 20:227-38. 2002
  35. ncbi request reprint Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells
    Woo Chan Park
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Int J Oncol 27:1459-66. 2005
    ..We conclude that the differential regulation of telomerase gene might be an important transition for tamoxifen resistance in T47D:A18 breast cancer cells...
  36. ncbi request reprint MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis
    Anait S Levenson
    Department of Orthopaedic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 65:10651-6. 2005
    ..Taken together, our results suggest that MCT-1 may contribute to the pathogenesis and progression of human breast cancer via at least two routes: promotion of angiogenesis through the decline of TSP1 and inhibition of apoptosis...
  37. ncbi request reprint Advances in endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Cancer Chemother Biol Response Modif 21:211-22. 2003
  38. ncbi request reprint The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Exp Biol Med (Maywood) 229:722-31. 2004
    ..This minireview will describe the current strategies for the treatment and prevention of breast cancer and present emerging new concepts about the consequences of exhaustive antiestrogen treatment on therapeutic resistance...
  39. ncbi request reprint Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha
    Anait S Levenson
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Cancer 104:587-96. 2003
    ..In summary, Res acts as an ER agonist at low doses but also activates ER-independent pathways, some of which inhibit cell growth...
  40. ncbi request reprint Chemoprevention of breast cancer: current and future prospects
    Sam G Pappas
    Department of Surgery and Molecular Pharmacology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Metastasis Rev 21:311-21. 2002
    ..These compounds will function as multifunctional medicines and will hold the promise of preventing breast and endometrial cancer, while providing the beneficial effects of preventing osteoporosis and coronary heart disease...
  41. ncbi request reprint Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro
    Robert T Chatterton
    Department of Obstetrics Gynecology, Northwestern University Medical School, 333 East Superior Street, Chicago, IL 60611, USA
    Cancer Lett 188:47-52. 2002
    ..We conclude that in the absence of PR, epithelial structures are resistant to the carcinogenic action of DMBA...
  42. ncbi request reprint Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor
    Anait S Levenson
    Robert H Lurie Comprehensive Cancer Center, The Fineberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer Res 62:4419-26. 2002
    ..A model for estradiol-like (survival) and antiestrogen-like (apoptosis) activities of SERMs on the basis of their gene expression profiles is suggested...
  43. pmc Bioluminescence imaging for assessment and normalization in transfected cell arrays
    Angela K Pannier
    Department of Interdepartmental Biological Sciences, Northwestern University, Evanston, Illinois
    Biotechnol Bioeng 98:486-97. 2007
    ..This system provides a tool for basic science research, with potential application for the development of patient specific therapies...
  44. ncbi request reprint Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2
    Barry D Gehm
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, 303 E Chicago Ave, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 88:223-34. 2004
    ..In contrast, mutation of AF-2 left both ligands with a limited ability to induced TGFalpha expression. In summary, the effect of modifying or deleting AF domains depends strongly on the ligand and the target gene...
  45. ncbi request reprint Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine of Northwestern University, 303 East Chicago Avenue, MS N505, Chicago, Illinois 60611, USA
    J Med Chem 46:883-908. 2003
  46. ncbi request reprint Acceptance of tamoxifen chemoprevention by physicians and women at risk
    Julia Tchou
    The Lynn Sage Breast Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 100:1800-6. 2004
    ..The purpose of the current study was to identify factors associated with being offered, and accepting, tamoxifen chemoprevention...
  47. ncbi request reprint Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens
    David Bentrem
    Robert H Lurie Comprehensive Cancer Center, and Department of Surgery, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Cancer Res 63:7490-6. 2003
    ..The observation that class I (planar) and class II (nonplanar) compounds have different mechanisms of estrogen action may have important implications for tissue selective modulation of the ER...
  48. ncbi request reprint Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells
    Hong Liu
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Int J Oncol 29:1237-46. 2006
    ..More importantly, these results provide a molecular basis for using gefitinib, BCRP inhibitors, and chemotherapeutic agents as combination therapy approaches in fulvestrant-resistant breast cancer...
  49. doi request reprint Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels
    Meiling Lu
    Cell Death Regulation Laboratory, Department of Medicine and Cell and Molecular Biology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Clin Cancer Res 14:3168-76. 2008
    ..We examined whether the nonsteroidal anti-inflammatory drug aspirin sensitized cancer cells to TRAIL agonists in vitro and in vivo and investigated the underlying mechanism...
  50. ncbi request reprint The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3
    Merideth C Kamradt
    Cell Death Regulation Laboratory, Department of Medicine and Cell, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611
    J Biol Chem 280:11059-66. 2005
    ..Moreover, these results demonstrate that targeted inhibition of alpha B-crystallin promotes TRAIL-induced apoptosis, thereby suggesting a novel strategy to overcome TRAIL resistance in cancer...
  51. ncbi request reprint Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
    Eric A Ariazi
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Mol Cancer Ther 6:2817-27. 2007
    ..We conclude that 17-hydroexemestane exerts biological effects as an androgen. These results may have important implications for long-term maintenance of patients with AIs...
  52. ncbi request reprint Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest
    Meiling Lu
    Cell Death Regulation Laboratory, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Biol Chem 280:6742-51. 2005
    ..We also demonstrate for the first time that TZDs promote TRAIL-induced apoptosis of breast cancer in vivo, suggesting that this combination may be an effective therapy for cancer...
  53. ncbi request reprint The biological role of estrogen receptors alpha and beta in cancer
    Sandra Timm Pearce
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Olson Pavilion, Room 8258, Northwestern University, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Crit Rev Oncol Hematol 50:3-22. 2004
    ..An ultimate goal of current research is to enhance the value of the separate estrogen receptors as targets for therapeutic intervention...

Research Grants2

  1. EFFECT OF RALOXIFENE ON SALIVARY STEROIDS
    VIRGIL JORDAN; Fiscal Year: 2002
    ..Most importantly, completion of the study will validate an important new methodology to monitor the ovarian effects of any new chemopreventive that can be used in premenopausal women. ..
  2. Pharmacogenetics of Sulfate Conjugation
    VIRGIL JORDAN; Fiscal Year: 2006
    ..These results will increase our understanding of the contribution of SULT1A1 pharmacogenetics to individual variation in response to estrogens and an important antiestrogen. ..